Daniel L. Suzman

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal et al. · The Oncologist · 2016 · 478 citations · Full text

Medicine, Oncology, Pharmacology +12

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 346 citations

Medicine, Oncology, Pharmacology +17

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Jaleh Fallah, Sundeep Agrawal, Haley Gittleman et al. · Clinical Cancer Research · 2022 · 220 citations · Full text

Medicine, Oncology, Pharmacology +17

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy

Daniel L. Suzman, Sundeep Agrawal, Yang‐Min Ning et al. · The Oncologist · 2018 · 200 citations · Full text

Medicine, Oncology, Pharmacology +15

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang et al. · The Oncologist · 2020 · 182 citations · Full text

Medicine, Gynecology, Oncology +14